IKT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
Today's Volume	52 493.00
Average Volume	136 877
Market Cap	13.21M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0.0150 (0.72%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.58
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

Volume Correlation

Long: 0.07 (neutral)

Short: -0.49 (neutral)

Signal:(55.207) Neutral

Inhibikase Therapeutics, Correlation

10 Most Positive Correlations
SVOK	0.82

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inhibikase Therapeutics, Correlation - Currency/Commodity

-0.70
( moderate negative )

0.00
( neutral )

-0.71
( moderate negative )

0.00
( neutral )

0.46
( neutral )

Inhibikase Therapeutics, Financials

Annual	2023
Revenue:	$260 500
Gross Profit:	$83 102.00 (31.90 %)
EPS:	$-3.57

Q4	2023
Revenue:	$1.00
Gross Profit:	$-6 567.00 (-656 700.00 %)
EPS:	$-0.680

Q3	2023
Revenue:	$79 569.00
Gross Profit:	$73 001.00 (91.75 %)
EPS:	$-0.860

Q2	2023
Revenue:	$116 410
Gross Profit:	$-42 794.00 (-36.76 %)
EPS:	$-1.110

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.